2 recruiting, 1 active not recruiting, 1 not yet recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Umoja Biopharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma UB-VV500, Rapamycin (sirolimus) - Multiple Myeloma in Relapse, Multiple Myeloma (MM) | Phase 1 | Not yet recruiting | Umoja Biopharma | 100 | 2026-10-01 | 2026-08-17 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies UB-VV111, rapamycin - Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL) | Phase 1 | Recruiting | Umoja Biopharma | 106 | 2025-03-10 | 2026-10-15 |
| A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma SCRI-E2CAR_EGFRtv1, UB_TT170 - Osteosarcoma | Phase 1 | Active not recruiting | Seattle Children's Hospital | 21 | 2022-05-20 | 2026-10-08 |
Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Bone Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Myeloma (1) · Osteosarcoma (1)
Sirolimus (3)
United States (3) · Australia (1)
Luke Walker, MD (3) · Catherine Albert, MD (1)